Ariad Stops Sales of Cancer Pill Iclusig

Oct 31, 2013


Ariad Pharmaceuticals, Cambridge, Mass., is suspending sales of its leukemia drug Iclusig because of heightened concerns that patients could suffer from life-threatening blood clots. Shares of the drug developer slid in afternoon trading. The company said that the Food and Drug Administration asked it to stop marketing the drug two days ago. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments